Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joyce S Plested

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
The Lancet. Infectious Diseases|March 9, 2024
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trialChijioke Bennett, Wayne Woo, Mark Bloch, et al.
JAMA Pediatrics|July 31, 2023
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical TrialBhagwat Gunale, Dhananjay Kapse, Sonali Kar, et al.
Scientific Reports|October 3, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adultsPrasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical TrialChijioke Bennett, E Joy Rivers, Wayne Woo, et al.
The New England Journal of Medicine|September 3, 2020
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineCheryl Keech, Gary Albert, Iksung Cho, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Human Vaccines & Immunotherapeutics|December 12, 2024
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M<sup>TM</sup> adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trialVivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, et al.
The Lancet. HIV|April 30, 2022
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialShabir A Madhi, Dhayendre Moodley, Sherika Hanley, et al.
The New England Journal of Medicine|May 5, 2021
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 VariantVivek Shinde, Sutika Bhikha, Zaheer Hoosain, et al.
The New England Journal of Medicine|July 30, 2020
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in InfantsShabir A Madhi, Fernando P Polack, Pedro A Piedra, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
The Lancet. Infectious Diseases|March 9, 2024
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trialChijioke Bennett, Wayne Woo, Mark Bloch, et al.
JAMA Pediatrics|July 31, 2023
Safety and Immunogenicity of SARS-CoV-2 Recombinant Spike Protein Vaccine in Children and Adolescents in India: A Phase 2-3 Randomized Clinical TrialBhagwat Gunale, Dhananjay Kapse, Sonali Kar, et al.
Scientific Reports|October 3, 2023
A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adultsPrasad S Kulkarni, Bhagwat Gunale, Sunil Kohli, et al.
The Journal of Infectious Diseases|July 25, 2024
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical TrialChijioke Bennett, E Joy Rivers, Wayne Woo, et al.
The New England Journal of Medicine|September 3, 2020
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle VaccineCheryl Keech, Gary Albert, Iksung Cho, et al.
The Lancet Regional Health. Southeast Asia|January 17, 2023
Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled studyPrasad S Kulkarni, Abhijit Kadam, Sheela Godbole, et al.
Human Vaccines & Immunotherapeutics|December 12, 2024
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-M<sup>TM</sup> adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trialVivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, et al.
The Lancet. HIV|April 30, 2022
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trialShabir A Madhi, Dhayendre Moodley, Sherika Hanley, et al.
The New England Journal of Medicine|May 5, 2021
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 VariantVivek Shinde, Sutika Bhikha, Zaheer Hoosain, et al.
The New England Journal of Medicine|July 30, 2020
Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in InfantsShabir A Madhi, Fernando P Polack, Pedro A Piedra, et al.
Pageof 5